| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8537846 | Pulmonary Pharmacology & Therapeutics | 2018 | 33 Pages |
Abstract
The developed model provides further details about the pharmacokinetics of nintedanib in patients with IPF and can be used for simulations exploring covariate effects and exposure-response analyses in this patient population.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Ulrike Schmid, Christiane Doege, Claudia Dallinger, Matthias Freiwald,